254 related articles for article (PubMed ID: 28552625)
41. Effectiveness of psoriatic arthritis therapies.
Gladman DD
Semin Arthritis Rheum; 2003 Aug; 33(1):29-37. PubMed ID: 12920694
[TBL] [Abstract][Full Text] [Related]
42. Elevated C-Reactive Protein Level Predicts Earlier Treatment with Tumor Necrosis Factor-Alpha Inhibitors in Psoriatic Arthritis.
Ofer-Shiber S; Molad Y
Isr Med Assoc J; 2016 May; 18(5):279-82. PubMed ID: 27430084
[TBL] [Abstract][Full Text] [Related]
43. Current approach to the management of psoriatic arthritis according to a sample of Italian rheumatologists.
Marchesoni A; Lubrano E; Manara M; Ramonda R; Salvarani C; Olivieri I
Clin Exp Rheumatol; 2016; 34(6):1051-1058. PubMed ID: 27462870
[TBL] [Abstract][Full Text] [Related]
44. The Role of Tumor Necrosis Factor-α Blockers in Psoriatic Disease. Therapeutic Options in Psoriatic Arthritis.
Addimanda O; Possemato N; Caruso A; Pipitone N; Salvarani C
J Rheumatol Suppl; 2015 Nov; 93():73-8. PubMed ID: 26523063
[TBL] [Abstract][Full Text] [Related]
45. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies.
Elyoussfi S; Thomas BJ; Ciurtin C
Rheumatol Int; 2016 May; 36(5):603-12. PubMed ID: 26892034
[TBL] [Abstract][Full Text] [Related]
46. Current concepts and new developments in the treatment of psoriatic arthritis.
Pipitone N; Kingsley GH; Manzo A; Scott DL; Pitzalis C
Rheumatology (Oxford); 2003 Oct; 42(10):1138-48. PubMed ID: 12810935
[TBL] [Abstract][Full Text] [Related]
47. Clinical Features of Psoriatic Arthritis: a Comprehensive Review of Unmet Clinical Needs.
McArdle A; Pennington S; FitzGerald O
Clin Rev Allergy Immunol; 2018 Dec; 55(3):271-294. PubMed ID: 28748366
[TBL] [Abstract][Full Text] [Related]
48. New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol.
Cauli A; Piga M; Lubrano E; Marchesoni A; Floris A; Mathieu A
J Rheumatol Suppl; 2015 Nov; 93():70-2. PubMed ID: 26523062
[TBL] [Abstract][Full Text] [Related]
49. Economic impact of biologic utilization patterns in patients with psoriatic arthritis.
Schwartzman S; Li Y; Zhou H; Palmer JB
Clin Rheumatol; 2017 Jul; 36(7):1579-1588. PubMed ID: 28474139
[TBL] [Abstract][Full Text] [Related]
50. Drug persistence, effectiveness and safety assessment of anti-TNF therapies in psoriatic arthritis.
Saad AA; Hyrich KL; Ashcroft DM
Expert Opin Drug Saf; 2011 Mar; 10(2):219-26. PubMed ID: 21208138
[TBL] [Abstract][Full Text] [Related]
51. Psoriatic arthritis in Canadian clinical practice: the PsA assessment in rheumatology.
Gladman DD; Chandran V; Thavaneswaran A; Zummer M
J Rheumatol; 2012 Sep; 39(9):1850-3. PubMed ID: 22859361
[TBL] [Abstract][Full Text] [Related]
52. Diagnosing and treating psoriatic arthritis: an update.
Boehncke WH; Qureshi A; Merola JF; Thaçi D; Krueger GG; Walsh J; Kim N; Gottlieb AB
Br J Dermatol; 2014 Apr; 170(4):772-86. PubMed ID: 24266754
[TBL] [Abstract][Full Text] [Related]
53. Treating psoriatic arthritis to target: discordance between physicians and patients' assessment, non-adherence, and restricted access to drugs precluded therapy escalation in a real-world cohort.
Ferreira MF; Kohem CL; Xavier RM; Abegg E; Martins OS; Resmini MB; de Mello AL; de Almeida Menegat F; Hax V; Gasparin AA; Brenol CV; de Andrade NPB; Viecceli D; Brenol JCT; Palominos PE
Clin Rheumatol; 2019 Mar; 38(3):961-968. PubMed ID: 30511296
[TBL] [Abstract][Full Text] [Related]
54. Golimumab for the treatment of psoriatic arthritis.
Yang H; Epstein D; Bojke L; Craig D; Light K; Bruce I; Sculpher M; Woolacott N
Health Technol Assess; 2011 May; 15 Suppl 1():87-95. PubMed ID: 21609657
[TBL] [Abstract][Full Text] [Related]
55. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
[TBL] [Abstract][Full Text] [Related]
56. High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission.
Araujo EG; Finzel S; Englbrecht M; Schreiber DA; Faustini F; Hueber A; Nas K; Rech J; Schett G
Ann Rheum Dis; 2015 Apr; 74(4):655-60. PubMed ID: 24336010
[TBL] [Abstract][Full Text] [Related]
57. Consensus on the management of patients with psoriatic arthritis in a dermatology setting.
Gisondi P; Altomare G; Ayala F; Conti A; Dapavo P; De Simone C; Foti C; Idolazzi L; Lubrano E; Malara G; Marchesoni A; Olivieri I; Parodi A; Peris K; Piaserico S; Salvarani C; Scarpa R; Girolomoni G
J Eur Acad Dermatol Venereol; 2018 Apr; 32(4):515-528. PubMed ID: 29220551
[TBL] [Abstract][Full Text] [Related]
58. Apremilast for the treatment of psoriatic arthritis.
Souto A; Gómez-Reino JJ
Expert Rev Clin Immunol; 2015; 11(12):1281-90. PubMed ID: 26503917
[TBL] [Abstract][Full Text] [Related]
59. An update on the diagnosis and management of psoriatic arthritis.
Weger W
G Ital Dermatol Venereol; 2011 Feb; 146(1):1-8. PubMed ID: 21317852
[TBL] [Abstract][Full Text] [Related]
60. Psoriatic arthritis: a review.
Amherd-Hoekstra A; Näher H; Lorenz HM; Enk AH
J Dtsch Dermatol Ges; 2010 May; 8(5):332-9. PubMed ID: 20015187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
